White, A., McKay, G. A. and Fisher, M. (2012) Drugs for diabetes: part 9 prescribing for patients with cardiac disease. British Journal of Cardiology, 19, pp. 85-89. (doi: 10.5837/bjc.2012.017)
Full text not currently available from Enlighten.
Abstract
Up to one-third of patients with heart disease have diabetes. Cardiological status should be considered when deciding on treatment for diabetes. Patients with stable coronary disease can be treated with metformin, sulphonylureas or pioglitazone. Following an acute coronary syndrome, intensive insulin therapy with multi-dose insulin has been shown to reduce mortality, and longerterm treatment with pioglitazone may reduce recurrent events. There is little trial information for glycaemia control in patients with chronic heart failure, and metformin and insulin are both frequently used. Dipeptidylpeptidase-4 (DPP-4) inhibitors are new oral antidiabetic drugs, which are weight neutral, and the injected glucagon-like peptide-1 (GLP-1) receptor agonists reduce weight. Long-term outcome studies are awaited to see if they have cardiovascular advantages in any particular group of patients.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | White, Dr Anna and McKay, Dr Gerard |
Authors: | White, A., McKay, G. A., and Fisher, M. |
College/School: | College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing |
Journal Name: | British Journal of Cardiology |
Journal Abbr.: | Br J Cardiol |
Publisher: | MediNews Limited |
ISSN: | 0969-6113 |
ISSN (Online): | 1753-4313 |
University Staff: Request a correction | Enlighten Editors: Update this record